MANKIND Mankind Pharma Q2 FY26 results (Jul–Sep 2025) and concall
Mankind Pharma reported a mixed Q2 FY26, with strong top-line growth driven by BSV consolidation and exports, but profitability was impacted by higher R&D and employee costs, leading to a 280 bps YoY EBITDA margin contraction. The domestic business saw outperformance in chronic segments but overall secondary sales lagged IPM due to GST-related disruptions and monsoon effects on OTC. Management acknowledged underperformance against internal expectations due to ongoing transformations but expects recovery in H2 FY26.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 3,199 | 3,079 | 3,570 | 3,697 |
| EBITDA | 816 | 683 | 847 | 921 |
| Net profit | 385 | 425 | 445 | 520 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
